| Brighter Future Health And Wellness | |
|
101 Downing Rd Kennebunk ME 04043-6047 | |
| (207) 523-9158 | |
| Not Available |
| Full Name | Brighter Future Health And Wellness |
|---|---|
| Speciality | Clinic/center - Mental Health (including Community Mental Health Center) |
| Location | 101 Downing Rd, Kennebunk, Maine |
| Authorized Official Name and Position | Sallie Alicia Mccourt Albert (OWNER) |
| Authorized Official Contact | 2075239158 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Brighter Future Health And Wellness 101 Downing Rd Kennebunk ME 04043-6047 Ph: () - | Brighter Future Health And Wellness 101 Downing Rd Kennebunk ME 04043-6047 Ph: (207) 523-9158 |
| NPI Number | 1427746189 |
|---|---|
| Provider Enumeration Date | 04/28/2023 |
| Last Update Date | 04/28/2023 |
| Certification Date | 04/28/2023 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427746189 | NPI | - | NPPES |
News Archive
Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.
Neuroscientists at UCL have, for the first time, identified abnormalities in the way memories are 'replayed' in the brains of people with schizophrenia; researchers say the pathbreaking study provides an entirely new basis for explaining many of the condition's core symptoms.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).
Cancer Research UK's Drug Development Office has opened the first trial of a new drug combination in patients with advanced solid tumours and in a subset of patients who have non-small cell lung cancer. This trial will combine two compounds that aim to starve the tumours while simultaneously blocking cancer cell growth.
› Verified 6 days ago
Marianne C. Berube Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 58 Portland Rd, Kennebunk, ME 04043 Phone: 207-432-2296 Fax: 207-799-9353 | |
Wayfinder Wellness And Psychotherapy Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 36 Main St Ste D, Kennebunk, ME 04043 Phone: 207-370-8329 | |
Sarah Swenson Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 58 Portland Rd Ste 12, Kennebunk, ME 04043 Phone: 207-468-3984 | |
React Behavioral Health, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5 Bragdon Ln Ste 3, Kennebunk, ME 04043 Phone: 207-251-5842 | |
Fran S Kessler, Lcsw Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32 Woodhaven Dr, Kennebunk, ME 04043 Phone: 207-332-8881 | |
Re/vision Enterprises, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5 Nason Court, Suite 7, Kennebunk, ME 04043 Phone: 207-985-3137 Fax: 207-985-2640 | |
Recovery Associates Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 62 Portland Rd, Kennebunk, ME 04043 Phone: 207-985-8900 |